Citadel Advisors
COLL icon

Citadel Advisors’s Collegium Pharmaceutical COLL Stock Holding History

Citadel Advisors’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,700
Closed -$200K – 12848
2025
Q1 		$200K Sell
6,700
-11,100
-62% -$339K ﹤0.01% 10445
2024
Q4 		$510K Sell
17,800
-3,200
-15% -$106K ﹤0.01% 8510
2024
Q3 		$811K Sell
21,000
-2,400
-10% -$85.6K ﹤0.01% 7275
2024
Q2 		$753K Sell
23,400
-17,300
-43% -$600K ﹤0.01% 7185
2024
Q1 		$1.58M Buy
40,700
+33,800
+490% +$1.18M ﹤0.01% 5988
2023
Q4 		$212K Buy
+6,900
New +$173K ﹤0.01% 9843
2023
Q3 		– Sell
-5,700
Closed -$122K – 14372
2023
Q2 		$122K Sell
5,700
-1,000
-15% -$22.7K ﹤0.01% 10622
2023
Q1 		$161K Sell
6,700
-7,500
-53% -$199K ﹤0.01% 10525
2022
Q4 		$329K Buy
14,200
+300
+2% +$6.05K ﹤0.01% 9108
2022
Q3 		$223K Sell
13,900
-700
-5% -$12.3K ﹤0.01% 10185
2022
Q2 		$259K Sell
14,600
-4,900
-25% -$82.4K ﹤0.01% 10141
2022
Q1 		$397K Buy
+19,500
New +$368K ﹤0.01% 9919
2021
Q2 		– Sell
-16,500
Closed -$391K – 13735
2021
Q1 		$391K Buy
16,500
+5,400
+49% +$128K ﹤0.01% 10236
2020
Q4 		$222K Buy
+11,100
New +$217K ﹤0.01% 9578
2020
Q3 		– Sell
-23,800
Closed -$417K – 10137
2020
Q2 		$417K Buy
23,800
+12,800
+116% +$251K ﹤0.01% 7380
2020
Q1 		$180K Buy
+11,000
New +$227K ﹤0.01% 8115
2018
Q4 		– Sell
-26,900
Closed -$397K – 9174
2018
Q3 		$397K Buy
26,900
+12,500
+87% +$222K ﹤0.01% 7086
2018
Q2 		$343K Buy
14,400
+4,500
+45% +$111K ﹤0.01% 6978
2018
Q1 		$253K Buy
+9,900
New +$236K ﹤0.01% 6994
2017
Q3 		– Sell
-11,900
Closed -$149K – 7584
2017
Q2 		$149K Buy
11,900
+1,500
+14% +$14.8K ﹤0.01% 6742
2017
Q1 		$105K Buy
+10,400
New +$155K ﹤0.01% 6841

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Citadel Advisors's COLL Position: Q1 2026 in Review

Citadel Advisors reduced its Collegium Pharmaceutical (COLL) stake by 7.4% in Q1 2026, selling an estimated $413K and leaving 121,366 shares worth $4.01M. The position accounts for ﹤0.01% of the portfolio, ranked #4706.

Citadel Advisors first reported a position in COLL in Q1 2017 and has held it in 34 quarters since. The position peaked at $15.9M in Q4 2017. 266 funds tracked by Wall St. Rank hold COLL as of Q1 2026.

  • Citadel Advisors held 121,366 shares of Collegium Pharmaceutical worth $4.01M as of Q1 2026.
  • Citadel Advisors sold 9,760 Collegium Pharmaceutical shares in Q1 2026, an estimated $413K.
  • Collegium Pharmaceutical made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4706 holding.
  • Citadel Advisors first reported a position in Collegium Pharmaceutical in Q1 2017 and has held it in 34 quarters since.
  • Citadel Advisors's Collegium Pharmaceutical position peaked at $15.9M in Q4 2017.
  • 266 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.